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Abstract 
THE ROLE OF SEVERAL KINASES IN MICE TOLERANT TO 
t,.9 -TETRAHYDROCANNABINOL. 
Matthew C. Lee 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 1 999 
Director: Sandra P. Welch, Ph.D., Department of Pharmacology and Toxicology 
It has been suggested that the CB 1 G-protein-coupled receptor is internalized 
following agonist binding and activation of the second messenger pathways. The process 
of desensitization and resensitization is intimately involved with receptor internalization. 
Phosphorylation alters tolerance to cannabinoids thus contributing to tolerance. It is 
proposed that phosphorylation enhances the down-regulation of the CB 1 receptor. These 
findings led us to look at which kinase(s) may be involved in cannabinoid tolerance. We 
therefore hypothesize that by preventing phosphorylation of the CB 1 receptor, we may 
reverse tolerance. We evaluated our hypothesis by testing the role of several kinases in 
tolerance: protein kinase A (PKA), protein kinase C (PKC), protein kinase G (PKG), 
Beta Adrenergic Receptor Kinase (�-ARK), Phosphatidylinositol 3-kinase (PI3K) and the 
src family tyrosine kinase. We also looked at cAMP and cGMP analogs. We evaluated 
PKA using KT5720, a PKA inhibitor; PKC using bisindolylmaleimide I, HCI (bis), a 
PKC inhibitor; PKG using KT5823, a PKG inhibitor; �-ARK using Low molecular 
x 
weight heparin (LMWH), a �-ARK inhibitor; PI3K using LY294002, a PI3K inhibitor 
and PP I a src family tyrosine kinase inhibitor. The cAMP analog was dibutyryl-cAMP 
and the cGMP analog was dibutyryl-cGMP. ICR mice were rendered tolerant to 1'/­
tetrahydrocannabinol (�9-THC) by administering injections of 20mg/kg �9-THC s.c. 
every 1 2  hours for 6 .5 days. The mice were subsequently challenged 24 hours later with 
an ED80 of �9-THC at 20Jlglmouse (i.t .) .  Antinociception was measured by the tail-flick 
test, %MPE's  and EDsO's were calculated. The PKG inhibitor, KTs823, showed no 
significant change in %MPE. The �-ARK inhibitor, LMWH,  showed no significant 
change in the %MPE. The PI3K inhibitor, L Y294002, showed no significant change in 
the %MPE. Inhibition of PKC, by bis had no effect on tolerance, but at a higher dose 
attenuated the antinociceptive effect of �9-THC in non-tolerant mice. PP l ,  the src family 
tyrosine kinase inhibitor, reversed tolerance. KTs720, the PKA inhibitor reversed �9_ 
THC tolerance. These data support a role for PKA and tyrosine kinase in 
phosphorylation events in THC tolerant mice. (Supported by N IDA grants K02DAOO l 86 
and PsODAOs274) .  
Introduction 
Background. Cannabis is one of the most controversial drugs of our time, even 
though it has been used for both recreational and medicinal purposes for centuries. In the 
United states, ranking only behind alcohol and tobacco, cannabis is one of the most 
commonly abused drugs. The use of Cannabis Sativa, also known as Indian Hemp, dates 
back over 1 2,000 years (Abel 1 979). Its uses include that of making clothes and rope by 
the ancient Chinese and Greeks. It was cultivated in Jamestown, Virginia for its fiber 
early i n  American history (Grinspoon and Bakalar 1 993) .  Medicinally it has long been 
used in China, India, the Middle East, South America and South Africa. The earliest 
references to i ts medicinal uses date back to 2700 BC (Grinspoon and Bakalar 1 993) .  
Uses in ancient China included treatment for constipation, malaria, rheumatic pains and 
female disorders. Around 2000 to 1 400 BC in India the euphoric properties were 
discovered, and cannabis was recommended for reducing fevers, producing sleep, 
stimulating the appetite, rel ieving headaches and curing venereal diseases (Mechoulam 
and Feigenbaum 1 987). 
It was not until 1 839 that cannabis was introduced into western medicine. During 
this t ime cannabis was found to be a very safe drug (Snyder 1 97 1 ,  Lemberger 1 984). In 
further experiments Snyder showed that high doses did not ki l l  animals .  He noted the 
therapeutic effects including anticonvulsant action, analgesia, antianxiety and antiemetic 
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properties humans. These reports made cannabis an acceptable form of medicine In 
England and other European countries. The medicinal use of cannabis waned in the 
United States and Europe at the tum twentieth century, due to the development of 
synthetic medicines (Adams and Martin 1 996). 
The rising fear of cannabis use in the United states began in the 1 920's, and the 
use of cannabis was abolished by the enaction of the Marijuana Tax act in 1 937 (Musto 
1987). Marijuana is a Mexican term that refers to cannabis leaves or other crude plant 
material. Despite the legal measures in the United States, cannabis was a major drug of 
abuse during the 1 960s with the peak use in the late 1 970s and early 1 980s. Since then, 
use declined to a low in 1 992, and has seemed to be on the rise since (Johnson et al. 
1 995). 
Cannabinoids are psychoactive compounds that are secreted as a resin from the 
flowering tops and leaves of the Cannabis Sativa, subspecies indica, plant. Cannabinoids 
are found in the highest concentration in the flowering tops of the plant, fol lowed by the 
leaves. Small amounts of cannabinoids are found in the stem and roots, but none in the 
seeds (Adams and Martin 1 996). More than 400 compounds are synthesized by the plant, 
more than 60 of which are related to L�?-THC. il9-THC is the prototypical cannabinoid 
and major psychoactive component in marijuana. It is rapidly metabolized to I 1 -hydroxy­
il9-THC, in vivo. Most of the other cannabinoids are inactive or weakly active (Abood et 
al. 1 996). il9 -THC is a non-crystalline, waxy-liquid substance at room temperature. The 
pharmacological activity of il9-THC is stereoselective, with the (-)-trans isomer having 
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6-100 times more potency than the (+ )-trans isomer, depending on the pharmacological 
test (Dewey et al. 1 984). 
The Cannabinoid Receptors. It was initially thought that due to the l ipophi l ic 
nature of /).9_ THC and the central depressant effects, cannabinoids medicated their actions 
through the disruption of membrane ordering, similar to the mechanism of general 
anesthetics (Paton and Pertwee 1 972; Lawrence and Gil l  1975) .  Four chemically distinct 
subclasses of compounds exist with pharmacological and behavioral similarities to /).9_ 
THC, including compounds with three rings, such as /).9-THC, bicyclic compounds (CP-
55940), aminoalkylindoles (Win 55 ,2 1 2 )  and eicosanoids (anandamide). The 
enantioselectivity of /).9-THC reinforced the notion that some cannabinoid actions may 
act through a receptor (Mechoulam et al. 1 988). Definitive evidence for a specific 
cannabinoid receptor became apparent when it was cloned (Matsuda et al. 1990). A clone 
isolated from a rat brain library had homology with other receptors that interacted with G 
proteins in the cell membrane. None of the traditional agonists of G proteins bound to 
this receptor clone. An identification breakthrough occurred with the discovery that the 
mRNA distribution of the receptor clone paralleled that of the cannabinoid receptor. 
Confirmation of the identity of the clone occurred when adenylyl cyclase was inhibited 
upon exposure to CP 55,940 and /).9-THC in cells transfected with this clone. Adenylyl 
cyclase in non-transfected cells did not respond to cannabinoids. CP 55 ,940 is a non­
classical , bicyclic cannabinoid with a 4-25 times greater potency than /).9-THC. Studies 
show that CP 55 ,940 cross-generalized in rat and monkey drug discrimination, and cross 
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tolerance developed between the two compounds (Gold et al. 1 992, Pert wee et al. 1 993). 
The human cannabinoid receptor was subsequently cloned and found to have almost 
identical homology to the rat receptor (Gerard et al. 1 99 1 ) . The cannabinoid receptor is 
l inked to a G; protein  which, when activated by phosphorylation, i nhibits the activity of 
adenylyl cyclase (Howlett and Fleming 1984). Adenylyl cyclase then cannot catalyze the 
conversion of ATP to the second messenger cyclic AMP (cAMP) (Howlett et al . 1 986). 
It has been shown electrophysiological ly that cannabinoids inhibit an omega conotoxin 
sensitive, high voltage-activated N-type calcium channel (Caufield and Brown 1 992, 
Mackie and Hi l le 1 992). Cannabanoids also have been reported to enhance the low­
voltage A-type potassium channels (Deadwyler et al . 1 993) .  
There are two cannabinoid receptors, CB 1 which is located primarily in the brain 
with the highest concentration in the substantia n igra pars reticula, globus palidus, and 
molecular layer of the cerebel lum (Felder et al. 1 993 ) and also to a lesser extent in the 
periphery in human peripheral blood lymphocytes (Bouaboula et al. 1 993) and mouse 
spleen cells ( Kaminski et al. 1 993); an amino-terminal variant of CB 1 receptor, the CB I A  
has also been discovered i n  brain and several peripheral tissues (Shire et al. 1 995); 
and CB2 which has been found on splenic macrophages (Munro et al. 1 993) .  The role or 
the receptors in  the spleen remains elusive. Even though the CB 1 and CB2 receptors 
only share 40% homology, Ll9-THC and CP 55 ,940 demonstrate similar binding affinity 
for both receptor SUbtypes. It was been demonstrated by Lement et al. ( 1 999) through 
studying CB 1 receptor knockout mice that the main pharmacological responses to Ll9_ 
THC, as well as the addictive properties of cannabinoids, are mostly mediated by the CB I 
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receptor. It was also suggested that the CB I receptors are required for the development 
of physical dependence or to obtain a complete manifestation of the somatic signs of 
opiate withdrawal . S ince cannabinoids are highly l ipid soluble they have been reported to 
partition into cell membranes and alter the acti vity of a number of membrane-associated 
enzymes, providing an alternate non-receptor-mediated mechanism of action 
(Makriyannis et al . ) .  In CHO cells transfected and not transfected with the CB I receptor, 
cannabinoid agonist-activated arachidonic acid release and an increase in i ntracellular 
calcium, as well as an inhibition of arachidonic acid uptake, suggest a CB I receptor 
independent mode of action (Felder et al. 1992). The receptor-independent actions 
require higher concentrations of agonist to mediate their effects where as the receptor 
dependent actions only require nanomolar concentrations of agonist (Felder et al . 1994). 
Cannabinoid receptor signaling. The CB I and CB2 receptors are 
heterotrimeric G-protein  coupled receptors of the inhibitory subtype, composed of a, � 
and y subunits. Upon a l igand binding to the receptor, affini ty of the a subunit  for GTP 
increases and affinity for GDP decreases, so the a subunit is able to bind and hydrolyze 
GTP. Also the binding of GTP decreases the affinity for the �y subunit, which then 
disassociates from the a subunit (Childers and Deadwyler 1996). The a subunit acts by 
inhibiting adenylyl cyclase, which then decreases the amount of cAMP which results in 
an increase potassium "A" current (Childers and Deadwyler 1996). CB I and CB2 
stimulation induces the inhibition of adenylate cyclase and the activation of MAPK 
(Rinaldi-Carmona et al . 1998). CB I activation has recently been shown to induce 
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immediate-early gene expression such as Krox 24 through a cAMP-independent pathway 
(Bouaboula et al. 1 995) This central cannabinoid receptor mediated effect was blocked 
by the CB l receptor antagonist S R 1 4 1 7 1 6A (Rinaldi-Carmona et al. 1 996). S ince Krox 
24 induction is  receptor-mediated, but cAMP-independent there must be another 
mechanism of CB 1 receptor-mediated effects besides through cAMP. From the 
observation of two independent signaling pathways, several conclusions have emerged: 
MAPK activation is mediated through the G�y subunit and adenylate cyclase responses 
are mediated through the Go.i subunit (Rinaldi-Carmona et al. 1 998). The tyrosine kinase 
inhibitor, herbimycin  A, has been shown to inhibit the induction of Krox 24, suggesting 
that a protein TK may be involved in the Gi stimulation of the gene expre sion 
(Bouaboula et al . 1 995). MAPKs, which become tyrosine phosphorylated in 
cannabinoid-treated cells, can also be blocked by TK inhibitors, again suggesting that TK 
may play a role in CB I receptor-mediated effects (Bouaboula et al . 1 995). 
MAPKs can be activated in response to both GPCR or receptor-tyrosine 
kinase (RTK) stimulation. Insul in receptors belong to the RTK family, and their 
stimulation by insulin has been shown to activate MAPKs in CHO cells (Bouaboula et al . 
1 997). S R 14 1 7 1 6A completely i nhibited insulin-activated MAPK in CHO cells 
transfected with the CB 1 receptor, giving rise to the fact that CB 1 activation is required 
for insulin activation of MAPK (Bouaboula et al . 1 997). This effect could not be 
extended to other RTKs (Bouaboula et al . 1 997). It has also been reported that activation 
of PI-3K upstream to the MAPKs is required for PTX-sensitive activation of MAPK by 
GPCR (Bouaboula et al . 1 997). Wortmannin, a PI-3K inhibitor, which is an early 
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intermediate of the G�r mediated MAPK signaling pathway, inhibitor resulted In 
significant inhibition of both CP-55 ,940 and insul in-mediated MAPK activation 
(Bouaboula et a1 . 1 997). In contrast to the classical EGF receptor paradigm, stimulation 
of the MAPK pathway by the IGF I RTK also requires the participation of G�r subunits 
derived from PTX-sensitive G proteins. Similar to the GPCR pathway, the IGF signal 
can be blocked by either PTX or by an inhibitor of G�r subunit-mediated signaling 
(Luttrell et at. 1 995) .  Thus upstream to Ras there is a convergence or common pathway 
of the IGF class of RTK with the GPCR signaling pathway. 
There have been other systems of cannabinoid receptor signal transduction 
pathways proposed. Some studies show that cannabinoids might activate the inositol 
phospholipid pathway. This pathway involves the receptor activating a G protein that in 
tum activates phospholipase C. Phosphol ipase C cleaves phosphatidylinositol-
bisphosphate (PIP2) into inositol-triphosophate ( IP3)and diacylglycerol (DAG). DAG 
activates PKC, and IP3 triggers calcium release from cellular stores. (Chaudry et at. 
1 988) .  Other studies show no effect on phospholipase C activity, and the generation of 
IP3 (Felder et at. 1 992). 
An abundance of evidence is  available that shows cannabinoids have effects on 
the biophysical properties of l ipid bilayers and biological membranes.  Specifically, the 
psychoactive cannabinoids, �9 -THC and I I _OH_�9 -THC, decrease the brain 
synaptosomal membrane lipid ordering, while the cannabinoids lacking psychoactive 
properties (cannabidiol and cannabinol) do not decrease ordering. This may play a part in 
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the mechanism of cannabinoids non-receptor mediated effects, including AA release, 
increase in intracellular calcium, and inhibition of AA uptake. It is thought the AA 
release may be due in part to inhibition of free fatty acid reacylation. It is possible PLA2 
is being activated while simultaneously acyl-transferase is being inhibited. PLA2 and AA 
release have been shown to depend on an increase in intracel lular calcium levels (Felder 
et al . 1 992). 
Endogenous Ligands. The first endogenous l igand for the cannabinoid receptor 
anandamide (ANA) was isolated in 1 992 by Devane et. al . It has a greater affinity for the 
CB I receptor than the CB2. It has both similarities and dissimilarities to the classic 
cannabinoids. Similarities exist in the interaction with a Gi protein, i nhibition of adenyly1 
cyclase and modulation of c-AMP levels in cell s  (Felder et al . 1 993, Vogel et al . 1 993) 
and inhibition of N-type calcium channels (Felder et al. 1 993, Mackie et al . 1 993) .  ANA 
is 4 to 20 times less potent than /19_ THC and has a shorter duration of action (Smith et al . 
1 994) .  ANA is structurally dissimilar to /19-THC and it also differs from the classic 
cannabinoids in that it is only a partial agonist at the N-type calcium channels, whereas 
the cannabinoids are ful l  agonists. ANA appears to display binding and functional 
properties similar to previously studied cannabinoid agonist, including the abi l ity to 
induce both receptor mediated and non-receptor mediated signaling (Felder et al . 1 993) .  
Anandamide produced similar pharmacological effects to THC, such as antinociception, 
catalepsy, hypomoti l ity and hypothermia, (Fride and Mechoularn 1 993) .  ANA has also 
been shown to be cross tolerant to /19_ THC (Pertwee et al. 1 993; Welch et al . 1 995) .  It is 
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interesting to note that t,9-THC, CP-55,940 and WIN 55,2 1 2-2 affected memory in  rats 
where anandamide and cannabidiol did not (Lichtman et al . 1 995). Is this due to sUbtypes 
of receptors with different specificities or i nteraction with NMDA receptors? The 
answers to these questions remain unanswered. 
The Cannabinoid Receptor Antagonist and Inverse Agonist. The antagonist 
SR I 4 1 7 1 6A, has a high affinity for the CB l receptor, but not the CB2 receptor (Rinaldi-
Carmona et. al . 1 994) .  In vitro, it antagonized both cannabinoid-induced inhibition of 
adenylyl cyclase activity in rat brain membranes and mouse vas deferens contractions; in 
vivo it antagonized behavioral effects of cannabinoid agonists (Rinaldi-Carmona et al . 
1 994) .  S R 14 1 7 1 6A also antagonized the discriminative stimulus effects of both t,9-THC 
in rats and rhesus monkeys (Wiley et al. 1 995) and CP 55 ,940 in rats (Wiley et al. 1 995). 
It has also been demonstrated that SR 14 1 7 1 6A not only functions as an antagonist of 
cannabinoid mediated effects, but also an inverse agonist (Bouaboula et al . 1 997). The 
inverse agonist property was shown through two different signal ing pathways, G[ly-
mediated MAPK and Gia-mediated AC responses. S R 1 4 1 7 1 6A reversed the increase in 
MAPK activation through the G[ly pathway. SR 1 4 1 7 1 6A also prevented the AC 
responses through the Gia pathway. In cells transfected with CB l receptors, SR 14 1 7 1 6A 
wil l  block insulin stimulated MAPK induction, but i n  wild type cells S R I 4 1 7 1 6A had no 
effect on insulin activated MAPK ( Bouaboula et al . 1 997). This effect seems only to be 
related to the PTX-sensitive RTKs including the insulin and IGF 1 receptors, not other 
RTKs. 
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General Effects of  Ll9.THC. The effects of THC are due to i t s  direct cellular actions on 
peripheraJ t issues, and due to its high l ipophilicity it is able to cross the blood brain 
barriers and cause CNS affects. Behavioral effects are characterized at low doses as a 
mixture of depressant and stimulatory effects and at higher doses as predominantly CNS 
depression (Dewey (986). The depressant affects of cannabinoids produce hyperreflexia. 
Cannabinoids generally cause a reduction in spontaneous locomotor activity (Little et al . 
(988) and a decrease in response rates with different reinforcement schedules (Carney et 
aJ. (979). Cannabinoids also impair learning and memory in rodents (Carlini  et aJ. ,  (970) 
and non-human primates (Ferraro and Gril ly (973) .  Other affects that have been shown 
in the mouse include hypothermia, immobility (catalepsy) and antinociception (Martin 
(985) .  
Cannabinoid·induced antinociception. Several possible transduction mechanisms for 
cannabinoid-induced spinal antinociception have been proposed, including modulation of 
adenylate cyclase, calcium, potassium, prostaglandins, and opioids. Cannabinoids have 
been shown to interact with c-AMP, potassium channels and opioids, but not calcium, in 
the production of antinociception in the spinal cord (Welch et al . (995) .  The 
administration of pertussis toxin, which prevents G; proteins from interacting with 
receptors, significantly attenuates or blocks the antinociception produced by cannabinoids 
i . t .  This action suggests the mechanism for antinociception is through the GPCR. 
Forskoli n  pretreatment, which stimulates adenylyl cyclase, there by increasing cAMP 
levels, significantly reduced the antinociception produced by L\9_ THC administered i . t. 
However the administration of dibutyryl cAMP fai led to alter the antinociception 
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produced by cannabinoids i . t . ,  but Cl-cAMP a stable analog of cAMP, significantly 
blocked the antinociceptive effects produced by i .t . administered cannabinoids. Thus, in 
the spinal cord, the antinociceptive effects of the cannabinoids seem to be produced via a 
Gi or Go protein  i n  conjunction with the modulation of cAMP because the anti nociceptive 
effects of i .t .  cannabinoids are blocked by pertussis toxin, forskolin and CI-cAMP (Welch 
et al. 1 995). The potency of numerous cannabinoids to inhibit cAMP formation in the 
neuroblastoma cell s  was found to correlate to antinociceptive effects of the drugs in vivo 
(Howlett et al, 1 986). Various calcium modulators were tested in combination with the 
cannabinoids and fai led to produce antinociception or alter the antinociception produced 
by administration of cannabinoids i . t .  Multiple potassium channel modulators 
admin istered i .t . failed to alter cannabinoid-induced antinociception with the exception, 
apamin, a blocker of small ( low) conductance calcium-gated potassium channels, which 
caused a parallel rightward shift in the dose-effect curves of several cannabinoids (Welch 
et al. 1 995). The kappa antagonist, nor-BN! (i . t . ) , and the kappa I receptor antagonist, 
naloxone benzoyl hydrazone (Nal-BZH), but not other opioid antagonists, blocks 
cannabinoid ( i . t . )- induced antinociception. This antinociceptive block does not occur due 
to direct interaction with the kappa receptor, because nor-BN! and nal-BZH fail to 
displace cannabinoid binding at the cannabinoid receptor. There is evidence to support 
an indirect interaction between the kappa receptor and �9-THC in a study in which the 
antinociceptive effects of �9 -THC are attenuated with antisera to Dynorphin A ( 1 -8) and 
Dynorphin A ( 1 - 1 7 )  (Rowen et al. 1 998). These data indicate that i nteraction of �9_ THC 
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with the cannabinoid receptor may cause release of endogenous spinal dynorphins or 
leucine enkephalin, a metabolite of dynorphin, leading to antinociception. Some possible 
points of interaction of the opioids and cannabinoids include the modulation of calcium, 
cAMP and potassium flux (Welch et al. 1 994) .  Data also supports the interaction of 
cannabinoids with several endogenous compounds that inhibit nociception. Data 
supports the involvement, in addition to opioids, PGE1, catecholamines, and 5-HT 
(Adams and Martin 1 996). 
Tolerance to Cannabinoids. Tolerance develops to the phannacological effects of 
cannabinoids in a variety of animal species, including pigeons, rodents, dogs, monkeys 
and rabbits. Tolerance has occurred to antinociception (Martin 1 985), anticonvulsant 
activity (Colasanti et al .  1 982), catalepsy (Pertwee 1 974), depression of locomotor 
activity (Karler et al . 1 984), hypothennia (Thompsom et al. 1 974), hypotension 
(Birmingham 1 973), corticosteroid release (Miczek and Dihit 1 980), ataxia in dogs 
(Martin et al . 1 976) and schedule- controlled behavior (McMillan et al. 1 970). Tolerance 
does not develop to all cannabinoid effects, such as ACTH secretion (Dewey et al . 1 970). 
Tolerance has also developed to cannabinoid-inhibition of adenylyl cyclase activity (Dil l  
and Howlett 1 988) .  It i s  interesting to note that tolerance developed to cannabinoid-
induced stimulation of prostaglandin E2 production and arachidonate release (Burstein et 
al. 1 985), but as was mentioned earlier the arachidonate release is not receptor-mediated. 
The precise mechanism of the development of tolerance is unknown. Changes at the 
cannabinoid receptor level fol lowing exposure to cannabinoids for a long period of time 
could result in confonnational changes in the receptor which would produce an altered 
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receptor structure, to which the l igand could not bind. Receptor internalization is another 
possible mechanism of tolerance. With receptor internalization, receptors are removed 
into the cytoplasm where they are either degraded or recycled. The number of receptors 
on the surface is decreased. Therefore, the binding to the receptor is decreased (Oviedo et 
al . 1 993, Rodriquez de Fonseca et al . 1 994). It has been proposed (Rinaldi-Carmona et al . 
1 998) that the rapid receptor internalization process is distinct from the slower process of 
receptor down-regulation. Evidence has been presented that shows the cannabinoid 
receptor is rapidly internalized fol lowing binding of an agonist. The internalization 
appears to occur through clathrin coated pits and is rapid and reversible after short 
treatment « 1 5 min.) ,  but not after long treatment (>90 min.) .  Internalization was not 
blocked by pretreatment with PTX and/or cholera toxin, suggesting activation of PTX- or 
CTX-sensitive G proteins was not required for internalization. This pathway is similar to 
the beta2-adrenergic receptor (Mackie 1 998). There is l i ttle evidence that chronic 
administration of cannabinoids alters disposition or metabol ism of cannabinoids in the 
brain or periphery (Oviedo et al . 1 993), suggesting that tolerance is pharmacodynamic in 
nature rather than a consequence of reduced bioavailability. In autoradiographic studies it 
wa shown that binding to the CB receptor was decreased, with no apparent regional 
selectivity, suggesting a lack of involvement of neural circuitry, second messengers, or 
other intervening variables that might lead to differential effects. The reductions appear 
to be receptor-mediated. In chronically treated animals the changes were the result in loss 
of binding capacity (Bmax) rather than a change in affinity (KD) (Oviedo et al . 1993) .  
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Figure 1 .  Down-regulation of the cannabinoid receptor. When THC or a C B  receptor 
l igand b inds to the cannabinoid receptor, the receptor is thought to be phosphorylated and 
rapidly internalized through clathrin-coated pits. Once in the cytosol several processes 
may occur: the receptor can be degraded, which would then require protein synthesis for 
a new receptor; or it can be dephosphorylated and recycled to the membrane. 
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This rules out the theory that there may be a conformational change in the receptor in 
chronically treated animals. 
It is  thought that the desensitization of the CB receptor may be similar to that of 
the beta adrenergic receptor (�-AR). The decreased responsiveness of the �-AR after 
stimulation with a near saturating concentration of l igand appears to be caused by rapid 
PKA and GRK phosphorylation. GRK phosphorylation in tum promotes �-arrestin 
binding and receptor internalization (Seibold et al. 1 998). In the fol lowing study, we 
inhibit �-ARK, with low molecular weight heparin .  If �-ARK plays a role in receptor 
activation upon l igand binding or role in receptor desensitization, then we may see an 
effect upon of acute or chronic affects of t,9 -THC upon inhibition of �-ARK. 
There is a bi-directional cross tolerance noted between the kappa opioids and t,9_ 
THC which implies a common mechanism of tolerance may underlie both classes of 
drugs (Rowen et al. 1 988) .  Kappa I antisense administration blocks the anti nociceptive 
effects of t,9-THC administered i . t .  The antinociceptive effects, but not the hypothermic, 
hypoactive or cataleptic are blocked by Dynorphin A ( 1 -8) and Dynorphin ( 1 - 1 7) antisera. 
Another mechanism of tolerance that must not be discounted is the role of the G protein 
subunit, Gi2a, which might be involved in opioid-induced tolerance expression. 
Antisense specific for the Gi2a subunit blocks morphine-induced antinociception and to 
different degrees also blocks the effects of different mu agonists. Therefore we may 
postulate that alterations i n  G proteins, or an uncoupling at the receptor, could account for 
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cannabinoid-induced tolerance via the interaction o f  the cannabinoids with kappa-opioids. 
(Rowen et al. 1998). 
The Role of Protein Kinase C in Cannabinoid effects. It has been shown that 
cannabinoids increases the phosphorylating activity of brain PKC in vitro (Hillard and 
Auchampach 1 994). Activation of PKC attenuates the modulation of N- and P/Q-type 
calcium currents and the Kir currents by G-protein coupled receptors. Fast modulation of 
all three channels is mediated by direct binding of G-protein  �y subunits to the channel 
itself (Zamponi et al. 1 997). Phosphorylating the CB I receptor with PKC strongly 
suppressed the modulation of P/Q type calcium channels and the Kir current by 
cannabinoids (Garcia et al . 1 998). Therefore, neurotransmitters coupled to PKC restore 
neuronal excitabil ity and synaptic activity reversing the effects of cannabinoids. Since 
PKC disrupts actions of cannabinoids by phosphorylating the CB I receptor, we evaluated 
the antinociceptive effects PKC in tolerant mice. In a tolerant mouse the cel ls function as 
if no t19 -THC is present, basically the cells have compensated and is able to function 
normally even though t19-THC is present. S ince PKC disrupts the actions of 
cannabinoids by phosphorylating the receptor, we also evaluated the effects of inhibition 
of PKC on acute antinociceptive effects of t19-THC. 
MAP Kinase and its Role in Cannabinoid Effects. In addition to cannabinoid-
induced signal transduction through cAMP accumulation and blockade of N-type calcium 
channels, several actions of cannabinoids may result from the increased level of tissue 
eicosaniods that occur in humans and animals treated with cannabinoids. Included in 
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the e effects are the effect o n  time estimation, heart rate acceleration, and the subjective 
'high' in humans; catalepsy induction in mice; and hypotension in dogs. The abi l ity of 
cannabinoids to mobilize arachidonic acid from cellular phospholipid storage sites by 
activation of PLA2 is thought to be the reason for the increase eicosanoid level .  
Anandarnide activates the MAP kinase signal transduction pathway in  mouse peritoneal 
cells, and can be blocked by pertussis toxin, suggesting the effect is receptor-mediated 
(Wartmann et al. 1 995). PLA2 is activated by the MAP kinase signal transduction 
pathway, which then causes and increase in arachidonic acid (Lin et aI . 1 993) .  
Phosphotidalinositol-3 kinase. It is unclear how PI3-K activity might contribute to 
activation of the MAPK pathway. It is known that PI3-K is an early i ntermediate of the 
G�y"mediated MAPK signaling pathway. It is interesting to note that 
phosphatidylinositol-3,4,5 ,-trisphosphate (PIP3) can directly i nteract with SH2 domains 
and might contribute to their recruitment. Partial reduction of SHC tyrosine 
phosphorylation fol lowing GPCR stimulation was detected upon inhibition of PI3-K 
(Daub et aI. 1 997). Therefore, we proposed to block PI3-K and reduce the SHC tyrosine 
phosphorylation. Such inhibition of PI3-K should block MAPK and cPLA2 release 
further down the pathway. If this block altered tolerance, then the action of PI3-K, or the 
results of activating the �y subunit could play a role in tolerance or antinociception. 
MAPK activation and interactions. MAPKs become activated in response to 
growth factors either through RTK or GPCR triggered signals. Transmission of these 
signals requires the formation of a complex between the Grb2 adapter protein with the 
guanine nucleotide exchange factor Sos, which upon recruitment to the plasma membrane 
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allows activation of the small G protein  Ras, resulting i n  subsequent activation of the 
MAPK pathway (Daub et aI, 1 997). Stimulation of various GPCRs rapidly induce 
tyrosine phosphorylation of the adapter protein SHC and SHC-Grb2 complex formation, 
steps that couple both GPCRs and RTKs to Ras. GPCR-mediated activation of the 
Ras/MAPK pathway has been reported to involve src function, leading to the idea that 
RTKs and Src family kinase might be required to initiate intracellular signaling cascades 
(Daub et a1. 1 997). A dominant negative mutant EGFR cell was evaluated and MAPK 
activation through a Gi coupled receptor was abolished (Daub et al. 1 997). Give such 
data indicating that GPCRs interact with RTKs in i ntracellular signali ng involving 
MAPK, we asked how the GPCR cannabinoid receptor and RTKs, interact and affect 
intracellular processes. An increase in SHC tyrosine phosphorylation and MAPK 
stimulation through both Gq- and Gj-coupled receptors was reduced greatly upon selective 
inhibition of EGFR function (Daub et al 1 997). Using PP l ,  a potent inhibitor of the src 
family of tyrosine kinases, we may be able to inhibit MAPK stimulation. Inhibition of 
MAPK is  proposed to address the possibil ity of antinociception or tolerance working 
through MAPK. 
PP I has been shown to suppress tyrosine phosphorylation of various Src 
substrates, which moderately increased EGF-induced EGFR tyrosine phosphorylation, 
while GPCR transactivation was inhibited somewhat. PP I targets essential signal ing 
elements upstream of Ras and downstream of the EGFR ( Daub et a1. 1 997) .  Stimulation 
of the CB I receptor with agonist leads to the activation of krox-24 and immediate early 
growth related gene. Krox-24 activation, which is blocked by PTX treatment cannot be 
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ascribed to known PTX-sensitive G-protein  pathways: adenylate cyclase, PLC and ion 
channel modulation. It has been shown, that herbimycin A, a tyrosine kinase inhibitor, 
inhibited the induction of krox-24, suggesting a tyrosine kinase may l ie on the route 
between Gi and krox-24 (Bouaboula 1 995). They also showed that MAPKs became 
tyrosine phosphorylated in cannabinoid-treated cells .  Thus we had reason to evaluate 
PP 1 in cannabinoid tolerant animals. 
With data suggesting that there are at least two, i f  not three pathways (ex subunit, 
�y subunit, and possibly ion channel modulation) activated by an agonist binding to the 
cannabinoid receptor, and several potential kinases which are activated by those 
pathways, we evaluated the role of inhibition of kinases down stream from the Gi-protein 
cannabinoid receptor. Our aim was to determine if tolerance and/or antinociception was 
altered upon kinase inhibition. We were, thus, addressing the fol lowing HYPOTHESIS: 
Delta-9 THC induced anti nociceptive tolerance is a function of the altered 
phosphorylation state of either the CB I receptor or proteins involved in the signal 
transduction of the CB I receptor. Our goal is  to address this hypothesis by the use 
of inhibitors of candidate kinases using drugs selective for such kinases. 
Methods 
Animal model of ,l9.THC tolerance. All studies were perfonned on male ICR 
mice. The mice were kept on a 1 2hourl l 2hour l ight/dark cycle and received food and 
water ad libitum. In the acute studies mice weighed 1 6  to 25 g, in chronic studies mice 
weighed 25 to 34 g upon testing. Mice were rendered tolerant to ,l9-THC over seven 
days. They received twice dai ly s.c. injections of ,l9-THC (20mglkg) for six days and on 
day seven they just received the morning dose. On the morning of day 8 mice were 
challenged with an ED-80 of ,l9_ THe. 
Intrathecal (i.t.) injections. I.t . injections were perfonned fol lowing the protocol 
of Hylden and Wilcox ( 1 983) .  Unaesthetized mice were injected with 5 ul of drug 
between the L5 and L6 area of the spinal cord with a 30-gauge, Y2-inch needle. 
The tail nick test. Mice were tested for antinociception by the tail flick 
procedure (0' Amour and Smith 1 94 1 ) . Reaction times of 2 to 4 seconds were employed 
for the control, while a time of 1 0  seconds was used for the cutoff to prevent tissue 
damage. Antinociception was quantified as the percent maximum possible effect 
(%MPE) fonnula: 
%MPE = 100 x [ (test - control)/( 1 0  - control)] 
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(Harris and Pierson, 1 964) .  Values were calculated for each mouse, using at least 4 mice 
per dose for which mean effect and standard error of the mean (SEM) were calculated for 
each dose. At least 3 doses of each test drug or combination of drugs were used to 
generated dose-response curves. 
Materials. Doses for all drugs used were determined in  naive animals using the 
maximal dose without toxicity. Time points were determined in  naive animals to where 
the drug had its peak effect. 1 00% dimethyl sulfoxide was purchased from Sigma 
Chemical Company (St .  Louis, MO). KT5720 purchased from Calbiochem (La Jolla, 
CA) was prepared in 1 00% DMSO and was injected i.t. at a dose of 2 .7llglmouse 1 5  
minutes prior to drug or vehicle ( i . t . ) .  The tail fl ick test was then conducted 1 5  minutes 
fol lowing the second injection. KT5823 purchased from Calbiochem (La Jolla, CA) was 
prepared in 1 00% DMSO and injected i . t .  at a dose of 2 .5llglmouse 1 5  minutes prior to 
drug or vehicle ( i .t . ) .  The tail fl ick test was then conducted 1 5  minutes following the 
second injection. Dibutyryl-cAMP ( 1OIlgimouse) and dibutyryl-cGMP (5Ilglmouse) were 
purchased from Calbiochem (La Jolla, CA) and were prepared in dH20 and injected i . t  
15  minutes prior to the i . t .  injection of drug or vehicle, fifteen minutes later the tai l flick 
test was conducted. �9-THC obtained from the National Institute of Drug Abuse (NIDA) 
and was prepared in  1 00% DMSO for acute tests, and I :  I :  1 8  [ I  part ethyl alcohol 
purchased from Aaper Alcohol and Chemical Company (Shelbyvil le, KY): I part 
emulphor EL-620: 1 8  parts 0.9% normal sali ne purchased from Baxter (Deerfield, II)] for 
tolerance studies. LY294002 was purchased from Biomol (Plymouth Meeting, PA) and 
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was prepared in 100% DMSO and injected i . t .  IS minutes prior to drug or vehicle, also 
injected i . t .  the tail flick test was then conducted 1 5  minutes following the second 
injection. Bisindolymaleimide I, HCL purchased from Calbiochem (La Jolla, CA) was 
prepared in dH20 and injected i . t .  (5Ilg/mouse) and (0.51lg/mouse) I S  minutes prior to 
drug or vehicle ( i .t . ) .  The tai l flick test was then conducted I S  minutes fol lowing the 
second injection. Low molecular weight heparin (LMWH) was purchased from S igma 
Chemical Corporation (St .  Louis, MO) and was prepared in dH20 and injected i . t .  
(30llg/mouse) IS  minutes preceding the i . t. injection of drug or vehicle, the tail flick test 
was then conducted I S  minutes fol lowing the second injection. PP I purchased from 
Alexis was prepared i n  100% DMSO and injected i . t .  1 0  minutes prior to the i . t .  injection 
drug or vehicle, with the administration of the tail fl ick test I S  minutes after the second 
i . t .  injection. 
Statistical analysis. Analysis of variance (ANOY A) was used to determine 
significant differences between control and treatment animal groups followed by 
Dunnett' s  t-test. These calculations were performed using StatYiew, version 5 1 2+ 
(BrainPower, Inc. Agoura Hil ls ,  CA). P values of less than 0.05 were deemed significant. 
Parallelism of the dose-response curves was determined by the methods of Tal larida and 
Murray ( 1 987) .  Potency ratios were determined using the methods of Coluhoun ( 1 997) .  
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First i.t. Drug action Dose Time Second i.t. inj . Time Test 
inj. (J.LgImouse) 
KT5720 PKA inhibitor 2 .7  1 5  �9-THC or veh 1 5  Tail fl ick 
minutes minutes 
KT5823 PKG inhibitor 2 .5 1 5  �9 _ THC or veh 1 5  Tail flick 
minutes minutes 
B is PKC inhibitor 0.5 and 5 .0 1 5  �9-THC or veh 1 5  Tail flic.k 
minutes minutes 
LMWH �-ARK 30 1 5  �9-THC or veh 1 5  Tail flick 
inhibitor minutes minutes 
LY294002 PI-3K inhibitor I S  �9-THC or veh 1 5  Tail flick 
minutes minutes 
PP I src TK 0.000 1 1 0  �9 _ THC or veh 1 5  Tail fli.ck 
inhibitor minutes minutes 
d-cAMP cAMP analog 1 0  1 5  �9-THC or veh 1 5  Tai l fl ick 
minutes minutes 
d-cGMP cGMP analog 5 I S  �9-THC or veh 1 5  Tail fJid 
minutes minutes 
Figure 2. Summary of drugs, actions, times between injections and test performed. 
Results 
The i . t. administration of KT5720, a protein kinase A (PKA) inhibitor, at a dose 
of 2.7llglmouse in  1 00% DMSO vehicle ( i . t . )  significantly (p<0.05) reversed L'l,9-THC 
anti nociceptive tolerance in a dose-dependent manner, as determined by the tail fl ick test. 
There was a leftward shift of the dose response curve. The ED50 in the L'l,9 -THC-tolerant 
mice was shifted from 79.63 (95% confidence l imits from 62. 1 0  to 1 02. 1 2) to 8.62 
Ilglmouse (95% confidence limi ts from 4.65 to 1 5 .99) in the KT5720 treated mice. The 
l ines were parallel and had a potency ratio of 8.32 with 95% confidence l imits. (Figure 3) .  
The protein  kinase G (PKG) inhibitor, KT5823, at a dose of 2.5llglmouse in 1 00% 
DMSO vehicle ( i . t . )  had no effect on L'l,9-THC antinociceptive tolerance. [2.4 %MPE in 
the tolerant mice compared to 6.7% in the tolerant animals treated with KT58. (Figure 
4) . ]  
Bisindolylmaleimide I, HCL (bis), a protein kinase C (PKC) inhibitor, at a dose of 
0.5llglmouse administered i . t .  in water vehicle did not affect the antinociceptive tolerance 
in mice. The %MPEs in the tolerant groups treated with bis compared to vehicle treated 
were not significantly different (20. 1 ± 1 5  vs. 1 4. 1±6.0, respectively) (Figure 5) .  At an 
increased dose of 51lglmouse there was not a significant shift i n  the ED50 values of the 
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Figure 3. The reversal of �9-THC by a PKA inhibitor ( KT5720). The graph shows a 
significant (*)  leftward shift of the curve representing the tolerant mice treated with 
KT5720 compared to the tolerant mice treated with vehicle. The effect of the PKA 
inhibitor on mice tolerant to �9 -THC is the reversal of tolerance. 
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Figure 4. A PKG inhibitor (KT5823) does not alter �9-THC antinociceptive tolerance. 
This is shown by the fact that there was not a significant change in tolerance in mice 
treated with KT5823 or vehicle. 
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Figure 5. The PKC inhibitor, bis, at a dose of O.5J..lglmouse did not alter .0.9-THC 
anti nociceptive tolerance. As can be seen from the graph, there is not a significant 
difference between the tolerant groups of mice treated with bis or vehicle. 
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tolerant mice treated with bis  compared to tolerant mice treated with vehicle (40.5 with 
95% confidence l imits of 3 1 .9 to 5 1 .4 vs. 80. 1 with 95% confidence l imits of 49.7 to 
1 28.98, respectively) (Figure 6). The l ines were not parallel in the tolerant mice and the 
potency ratio was 2 .04. Interesting though, in the non-tolerant mice there was an 
attenuation of the antinociceptive effect of �9 -THe. There was a significant (p<O.OS ) 
rightward shift in the dose-response curve. The EDSO was shifted from 7. 1 (95% 
confidence limits from 4.5 to 1 1 .2 )  in the vehicle-treated non-tolerant animal to 26.3 
(95% confidence l imits from 1 5 . 5  to 44.8 )  in the bis treated non-tolerant animal. The 
l ines on the graph are parallel and the potency ratio is 3 .6. 
Low molecular weight heparin (LMWH), which inhibits beta adrenergic receptor 
kinase (�-ARK), at a dose of 30 Ilg/mouse in water vehicle administered i . t .  did not affect 
the antinociceptive tolerance in the mice. The %MPE in the tolerant group treated with 
LMWH (S .2± 1 .8 )  was not significantly different than the vehicle treated tolerant group 
( l 4. 1 ±6.0), (Figure 7 ) . 
L Y294002, the a phosphatidylinositol-3-kinase inhibitor, administered i .t .  in 
1 00% DMSO vehicle at a dose of O. l llg/mouse did not significantly alter �9-THC 
antinociceptive tolerance in mice, (Figure 8) .  The L Y294002-treated tolerant mice had a 
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1 000 
Figure 6. The PKC inhibitor bis, at a dose of 5!J.glmouse attenuated the effects of t/­
THC in non-tolerant mice. As can be seen from the graph, there was a significant ( * )  
rightward shift of  the curve representing non-tolerant treated mice. 
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Figure 7. The �-ARK inhibitor, LMWH, did not significantly alter il9-THC 
antinociceptive tolerance. As can be seen from the graph there is not much change 
between the vehicle and LMWH treated tolerant mice. 
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Figure 8. The PI3-K inhibitor, L Y294002, did not significantly affect antinociceptive 
tolerance. This can be seen from the graph in that there is not a significant difference 
between the L Y294002 and vehicle treated tolerant animals. 
%MPE of 9.5±9.5 compared to the tolerant vehicle treated mice who had a %MPE of 
2 .4± 1 . 1 .  
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We also looked at PP I which is a src family tyrosine kinase. Since the �y subunit 
of the cannabinoid receptor interacts with tyrosine kinase to activate MAPK, we wanted 
to look at what would happen if this pathway was disrupted. At a dose of 
0.000 I Ilglmouse, in 1 00% DMSO vehicle administered i . t . ,  PP I significantly (p<0.05) 
reversed �9 -THC anti nociceptive tolerance in mice . The O.OOO l llgimouse dose was 
shown to be inactive (%MPE 3.7±O.8) in the tail fl ick test in naive mice, but in the non­
tolerant group in had a %MPE of 43.7± 1 9.6. The non-tolerant vehicle treated group also 
had a h igh %MPE (45 .3± 1 9 .2) .  (Figure 9). At doses of O.OO l llgimouse and higher PP I 
shows a variable anti nociceptive affect 
The next step was to look at potentiation of tolerance. If PKA inhibition reversed 
tolerance, what would happen if a cAMP analog was given? In order to tell whether of 
not there was a potentiation, the dose of �9-THC had to be raised to I OOllgimouse to get 
around a 50% MPE in the tolerant mice. Dibutyryl cyclic-GMP at 51lglmouse in water 
vehicle administered i . t .  did not significantly potentiate tolerance, a 35.5±20A %MPE in 
the tolerant animals compared with a 45.8±22.5 %MPE in the drug-treated animals 
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� P P 1  (0.0001 ).Ig1mouse)->69-THC(20).lg/mouse) 
Figure 9. The src family tyrosine kinase, PP I ,  reversed L'l9 -THC antinociceptive 
tolerance. It is shown in the graph that there was a significant reversal of L'l9-THC 
antinociceptive tolerance in tolerant mice treated with PP I .  However the graph also 
shows a PP I effect alone and a vehicle effect in the non-tolerant group. 
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Figure 10. Dibutyryl-cGMP does not enhance .0.9-THC antinociceptive tolerance. The 
graph shows no significant change between the dibutyryl-cGMP treated tolerant mice and 
the vehicle treated tolerant mice. 
(Figure 10) .  Dibutyryl cyclic-AMP at a dose of 1 0�g/mouse in water vehicle 
administered i . t .  also did not potentiate .0.9-THC antinociceptive tolerance, a 54.7± 1 3 .8  
%MPE in the tolerant animals compared to 45.8±22 .5  %MPE in the drug treated animals. 
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Even though it was not significant dibutyryl-cAMP seemed to attenuate the effects of !:l9_ 
THC in the non-tolerant animals (Figure 1 2) . 
Kinase 
PKA 
PKG 
PKC 
PD-K 
Tyrosine kinase 
�-ARK 
Inhibitor Effect on tolerance 
KT5720 Reversal 
KT5823 No change 
Bisindolylmaleimide I, HCl No change 
LY294002 No change 
PP 1 Reversal 
Low molecular weight heparin No change 
Figure 1 1. Summary of the kinases putatively inhibited, inhibitor and the effect on 
tolerance. 
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Figure 1 2. Dibutyryl-cAMP does not enhance t.9-THC antinociceptive tolerance_ 
Although not significant it does appear to attenuate the antinociceptive effects in non­
tolerant mice. It can be seen in the graph that enhancement does not occur because there 
is no significant change in %MPE in the tolerant animals treated with dibutyryl-cAMP or 
vehicle. 
Discussion 
The question I sought to address in these studies was: what role do various 
kinases play in �9-THC anti nociceptive tolerance? We evaluated kinases that were 
downstream from the cannabinoid receptor (PKA, PI3-K, TK), that may interact directly 
with the receptor (PKA, �-ARK, PKC) and others that act in different pathways (PKC, 
PKG). This discussion begins with kinases downstream from the a subunit, then goes to 
kinases downstream to the �y subunit, and ends with the "others" group. 
When a l igand binds to a GPCR, as the cannabinoid receptor, there is a decreased 
affinity between the a and �y subunits and they differentiate from one another. In the 
acute model of �9-THC exposure the a subunit wil l  cause a decrease in adenyl ate cyclase 
which then decreases cAMP fol lowed by a decrease in PKA. There is also an associated 
opening of low voltage potassium channels leading to an efflux of potassium and a 
modulation of calcium channels leading to decreased calcium conductance. In the 
chronical ly treated �9-THC model downstream from the a subunit there is a 
compensatory increase in adenylate cyclase, cAMP and PKA. The is no longer a �9-THC 
induced modulation of potassium and calcium channels. 
The intra-thecal administration of the protein kinase A inhibitor KT5720 reversed 
the antinociceptive tolerance of �9-THC. This indicates that protein kinase A plays a role 
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in the mechanism of �9-THC anti nociceptive tolerance whether it i s  direct or indirect is  
yet to be determined. PKA could be responsible for phosphorylating the CB I receptor 
upon binding of the l igand to the receptor, this activation could result in a chain of events 
one of which the end result is  antinociception. PKA also could be increasing potassium 
conductance through phosphorylation of the potassium channel, causing the cell to be 
hyperpolarized and unable to fire. Other possible roles of PKA in �9-THC mediated 
tolerance includes the possibility that PKA is rapidly and continuously phosphorylating 
the CB 1 receptor when it is  down-regulated into the cytosol in tolerant animals. Our lab 
has shown that receptor density does not change in mice tolerant to �9-THC, the down-
regulated receptors are not being degraded and new receptors are not being synthesized, 
or both processes are going at the same rate, the former is more plausible. The receptors 
are rapidly internalized upon exposure to cannabinoids (Mackie et al. 1 998) .  It has been 
suggested that the rapid internalization process of the cannabinoid receptor is distinct 
from the slower process of receptor down-regulation. As the cell becomes tolerant the 
internalization of the receptor may get longer and longer as the cell undergoes 
compensation. Once the cell is tolerant there will be an increased production of PKA to 
make up for decrease caused by �9-THC. These higher levels of PKA, compared to 
initial exposure could be responsible for a continuous phosphorylation of the CB I 
receptor while i n  the cytosol. This continued phosphorylation might be what keeps the 
receptor down-regulated in the cytosol. Upon inhibition of PKA the receptor will no 
longer be phosphorylated and could therefore be recycled to the membrane where it will 
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be active and capable of binding to the l igand again .  If the phosphorylation is not halted, 
and the receptor is kept in the cytosol ,  eventually it wil l be degraded, requiring mRNA for 
new protein synthesis. 
PKA could be responsible for the phosphorylation of the N-type calcium channels 
and potassium channels giving rise to the hyper-polarized state of a naive cell and 
resulting in antinociception. Upon inhibiting PKA in the tolerant animal, the 
phosphorylated channels become dephosphorylated and are therefore inactive again 
(potassium conductance is increased and calcium conductance is decreased), giving rise 
to the antinociceptive effects of f19-THC. We know, apamin, a blocker of small ( low) 
conductance calcium-gated potassium channels blocked the antinociceptive effects of i . t .  
administered cannabinoids (Welch 1995). However, i . t .  administration of cannabinoids 
are not sensitive to calcium modulation and thus may not directly involve calcium 
modulation (Welch 1 995). This leads me to believe the spinal mediated antinociception 
does not involve calcium channels. 
If PKA reverses cannabinoid anti nociceptive tolerance, what would happen if we 
gave a cAMP analog? We would think that a cAMP analog would enhance tolerance. In 
a non-tolerant cell exposed to cannabinoids cAMP is decreased, but in the presence of 
forskolin, which increases cAMP or CI-cAMP, a cAMP analog antinociception is 
attenuated (Cook et al . 1 995). But, i n  our case dibutyryl-cAMP did not enhance 
tolerance, though it did, but not significantly attenuate antinociception in the non-tolerant 
mice. It would be interesting to see what happens to cannabinoid tolerance in forskolin 
treated animals or with a different cAMP analog that is more potent. 
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Unsure as to whether or not the Goo mediated signaling pathway through cAMP 
was responsible for antinociception, we also wanted to look at kinases involved in the 
GJ3y-mediated signal ing pathway. PI-3 kinase and tyrosine kinase work downstream from 
the �y subunit of the GPCR, these kinases are generally associated with growth and 
differentiation. With the membrane destabil izing activity of cannabinoids and release of 
free arachidonic acid they might play a role in antinociception. The first of these being 
LY294002, a specific phosphatidylinositol 3-kinase inhibitor. PI3-K is an enzyme 
implicated in growth factor signal transduction by associating with receptor and non-
receptor tyrosine kinases (Vlahos et al . 1 994). PTX-sensitive RTKs and GPCRs 
converge or share a common pathway upstream from ras, which leads to the activation of 
MAPK. Our goal was to see if by blocking a kinase or kinases in the pathway, would we 
affect tolerance. In the case of blocking PI-3K tolerance was not affected. However the 
blockade of the src family tyrosine kinase reversed tolerance. Was i t  a true reversal? At 
higher doses the inhibitor, PP I is variably antinociceptive. In the non-tolerant groups 
PP I had a small antinocicepti ve effect as well as the vehicle. What is a possible 
explanation of a reversal of tolerance? By blocking a tyrosine kinase we may be 
inhibiting downstream actions of the �y subunit, that may be necessary to maintain a 
tolerant state or we may be bypassing the traditional route of antinociception, the mice are 
still tolerant to t.9-THC, but by inhibiting tyrosine kinase in  the presence of t.9-THC 
antinociception is the result. Possibly by inhibiting MAPK and/or PLA2 in the tolerant 
animal reverses tolerance. We would think, that since PP I reversed tolerance, L Y294002 
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would also. Looking at figures 1 3  and 14, PI3-K is necessary for ras formation. P13-K is 
also necessary to produce PI345P3 which is required for the complex to form. By 
i nhibiting either one of these steps L Y294002 should reverse tolerance if PP 1 is working 
through this same path to reverse tolerance, but it doesn' t .  Two, of the many possible 
explanations are: 1 )PP 1 is not working at the complex formation, or L Y294002 is not 
getting to the site of action. It would be interesting to look at other TK inhibitors or if 
tolerance can be enhanced through a tyrosine kinase analog, this would help clarify how 
this kinase may be working in tolerance reversal . Further studies need to be conducted 
looking the role of the �y subunit and tyrosine kinases and their role in central 
cannabinoid effects. 
In addition to kinases downstream to the a and �y subunits we also looked at 
other kinases. �-ARK is known to phosphorylate the �-AR and is a potential candidate 
for phosphorylating the cannabinoid receptor so it can be internalized in a clathrin coated 
pit and it is thus desensitized. If this were correct, then by blocking �-ARK with LMWH 
we could prevent receptor phosphorylation and possibly desensitization or down-
regulation. S ince LMWH was inactive it appears that the cannabinoid receptor is not 
phosphorylated by �-ARK and this kinase is not responsible for the desensitization of the 
receptor. Another possible kinase that could activate the CB 1 receptor is �-ARK, of the 
GRK family of kinases. �-ARK also known as GRK2, is thought to possibly to be 
involved in the desensitization of the beta adrenergic receptor. Mackie et al . in 1 998 
noted that the CB I receptor is internalized following a pathway grossly sirilllar to the one 
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used by the beta2-adrenergic receptor. Our data indicate that �-ARK does not play a role 
in receptor down regulation in mice tolerant to �9-THC, since LMWH does not affect the 
tolerance. If �-ARK plays a role in cannabinoid induced antinociception it is yet to be 
determined. 
PKG is known to interact with cGMP and nitric oxide . The inhibition of PKG did 
not reverse tolerance. The cGMP analog we looked at, dibutyryl-cGMP did not enhance 
tolerance. 
PKC may act directly on the receptor and/or downstream from the receptor. It has 
been shown that cannabinoids i ncrease brain protein kinase C activity in vitro (Hillard 
and Auchampach 1 994) .  So what happens if we inhibit PKC in tolerant animals? We 
showed at two different doses that tolerance to cannabinoids was not affected by 
i nhibiting PKC. It was shown at the higher dose that inhibiting PKC attenuated the 
effects of �9 -THC in non-tolerant animals. Hil lard et al. in 1 993 showed that 
cannabinoids increase the levels of PKC in rat brain and that these increased levels are 
responsible for reestablishing neuronal excitabil ity. Therefore we would expect the 
inhibition of PKC to prolong the effects �9-THC, but this is not what we saw. If 
inhibiting PKC attenuates the effects of cannabinoid-induced antinociception, it might be 
likely that these increased levels of PKC may be at least partially responsible for 
cannabinoid-induced antinociception. 
In summary, the data presented in this thesis demonstrates that by inhibiting PKA 
and tyrosine kinase �9-THC antinociceptive tolerance can be reversed. It seems l ikely 
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that these two kinases work independent of one another. The other kinases that were 
inhibited including: PKG, PKC, PI3-K and �-ARK did not alter tolerance. However, the 
higher dose of PKC was shown to attenuate the effects of t.9-THC in the non-tolerant 
ffilce. The cAMP and cGMP analogs had no significant effects on tolerance 
enhancement. 
Even though a kinase or analog did not affect tolerance we must not discount its 
possible effects or assume it does not alter tolerance. It is possible the drug may not reach 
the site of action, i t  i s  degraded to rapidly to exert i ts affect or inappropriate time points 
and doses were chosen, even though attempts were made to optimize both. 
A future direction would be to evaluate phosphorylation state of the receptor. If 
PKA is responsible for the initial desensit ization or maintaining the down-regulated state 
of the receptor we would expect to see the receptor in the phosphorylated state in tolerant 
animals. We would also expect to see a de phosphorylated receptor in spinal cord tissue 
that had been treated with the PKA inhibitor immediately prior to harvest. 
In order to produce new and more specific drugs to treat humans, we must first 
understand their mechanism of action. The goal of this research was to evaluate the 
underlying mechanisms for t.9-THC antinociceptive tolerance. In an attempt to one day 
prevent tolerance development i n  cl inical situations. 
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� krox 24 
Figure 13. Putative pathway, in the acute model of �9-THC exposure, of second 
messengers, kinases and where the kinase inhibitors may work. This figure shows that 
the ai subunit disassociates from the �y subunit. The a subunit decreases cAMP, 
adenylyl cyclase and PKA. The decrease in PKA could the be responsible for the: 
decrease in calcium conductance and increase in potassium conductance. The �y subunit 
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goes the other way allowing a complex to be fonned with second messengers down­
stream from the receptor tyrosine kinase (RTK), this convergence of pathways is 
upstre� from ras: The P1345P3 is also necessary for the complex fonnation. The end 
result IS a modulatlOn of phospholipase A2. 
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Figure 1 4. Putative pathway of second messengers and possible places of action on 
kinase inhibitors in the il9-THC tolerant model .  Downstream from the ex subunit there is 
a compensatory increase in AC, cAMP and PKA. Potassium efflux decreases and 
calcium conductance increases. Inhibiting PKA and the src TK reverses tolerance. Since 
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inhibiting the src TK reverses tolerance it would seem that inhibiting PI3-K would also 
reverse tolerance, but it doesn' t .  
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